BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31681835)

  • 1. BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
    Miah S; Banks CAS; Ogunbolude Y; Bagu ET; Berg JM; Saraf A; Tettey TT; Hattem G; Dayebgadoh G; Kempf CG; Sardiu M; Napper S; Florens L; Lukong KE; Washburn MP
    Sci Adv; 2019 Oct; 5(10):eaaw3113. PubMed ID: 31681835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
    Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
    PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
    Sun B; Fan Y; Yang A; Liang L; Cao J
    J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4.
    Lee CC; Yang WH; Li CH; Cheng YW; Tsai CH; Kang JJ
    Cancer Lett; 2016 Jul; 376(2):211-7. PubMed ID: 27060206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
    Weaver AM; Silva CM
    Breast Cancer Res; 2007; 9(6):R79. PubMed ID: 17997837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
    Castro NE; Lange CA
    Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
    Ai M; Liang K; Lu Y; Qiu S; Fan Z
    Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner.
    Kaul R; Risinger AL; Mooberry SL
    Br J Cancer; 2019 Oct; 121(7):611-621. PubMed ID: 31481735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
    Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
    Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-362 negatively and positively regulates SMAD4 expression in TGF-β/SMAD signaling to suppress cell migration and invasion.
    Cheng HP; Huang CJ; Tsai ML; Ong HT; Cheong SK; Choo KB; Chiou SH
    Int J Med Sci; 2021; 18(8):1798-1809. PubMed ID: 33746597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion.
    Sun J; He H; Pillai S; Xiong Y; Challa S; Xu L; Chellappan S; Yang S
    J Biol Chem; 2013 Dec; 288(52):36971-82. PubMed ID: 24235142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
    Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
    Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
    Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
    Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
    Ai M; Qiu S; Lu Y; Fan Z
    Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
    Gao Y; Cimica V; Reich NC
    J Biol Chem; 2012 Jun; 287(25):20904-12. PubMed ID: 22547065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
    Shen CH; Chen HY; Lin MS; Li FY; Chang CC; Kuo ML; Settleman J; Chen RH
    Cancer Res; 2008 Oct; 68(19):7779-87. PubMed ID: 18829532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
    Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
    Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression.
    Mandal G; Biswas S; Roy Chowdhury S; Chatterjee A; Purohit S; Khamaru P; Chakraborty S; Mandal PK; Gupta A; de la Mare JA; Edkins AL; Bhattacharyya A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2053-2066. PubMed ID: 29526821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression.
    Lukong KE; Larocque D; Tyner AL; Richard S
    J Biol Chem; 2005 Nov; 280(46):38639-47. PubMed ID: 16179349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis.
    Wu Y; Yu X; Yi X; Wu K; Dwabe S; Atefi M; Elshimali Y; Kemp KT; Bhat K; Haro J; Sarkissyan M; Vadgama JV
    Cancer Res; 2017 Mar; 77(6):1383-1394. PubMed ID: 28115363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.